Find Faculty Members at MUSC.

Andrew G Jakymiw Ph.D.

Provider Image
Rank
  • Assistant Professor
College
  • College of Dental Medicine
Department
  • Oral Health Sciences
Academic Focus
  • RNA interference (RNAi)-based therapeutics; cell-penetrating peptides
  • RNA silencing
  • Oral cancer

Locations

Office Location
street
room

Biography

Education:

PhD, University of Calgary, Biochemistry & Molecular Biology

Postdoctoral training, University of Florida (UFlorida)

 

Honors and Awards:

Canadian Institutes for Health Research Studentship (1997-2002)

Alberta Heritage Foundation for Medical Research Incentive Award (2001-2002)

Alberta Heritage Foundation for Medical Research Studentship Award (2002-2003)

American Society for Cell Biology Postdoctoral Travel Award (2005) 

Bankhead-Coley Florida Cancer Program New Investigator Research Grant (2008-2011)

K99/R00 NIH Pathway to Independence Award (2008-2014)   

 

Professional Experience:

2007 – 2010: Research Assistant Professor, UFlorida, Oral Biology

2010 – Present: Assistant Professor, MUSC, Oral Health Sciences

2012 – Present: Adjunct Assistant Professor, Clemson University, Bioengineering 

  

Research Interests:

Dr. Jakymiw’s research focuses on the study of RNAi-based therapies for oral cancer.  In particular, his lab is currently involved in developing cell penetrating peptide-mediated targeted delivery strategies of therapeutic siRNA molecules for the treatment of oral cancer.  Moreover, his laboratory is also pursuing the study of RNA silencing biology and how dysregulation of its molecular components can contribute to disease, in particular oral cancer.  The goal of his research is to gain further insights into the molecular causes of oral cancer, identify novel biomarkers for this disease, and develop novel therapeutic strategies for treating oral cancer.

 

Recent Publications:

Alexander-Bryant AA, Zhang H, Attaway CC, Pugh W, Eggart L, Sansevere RM, Andino LM, Dinh L, Cantini LP, and Jakymiw A. Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo. Oral Oncology 72:123-131, 2017. PMID: 28797448

Alexander-Bryant AA, Dumitriu A, Attaway CC, Yu H, Jakymiw A. Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo. Journal of Controlled Release 218:72-81, 2015. PMID: 26386438, PMCID: PMC4646222

Cantini L, Andino LM, Attaway CC, Butler B, Dumitriu A, Blackshaw A, Jakymiw A. Identification and characterization of Dicer1e, a Dicer1 protein variant, in oral cancer cells. Molecular Cancer 13:190, 2014. PMID: 25115815, PMCID: PMC4141963

Cantini L, Attaway CC, Butler B, Andino LM, Sokolosky ML, Jakymiw A. Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. PLoS ONE 8(9):e73348, 2013. PMID: 24019920, PMCID: PMC3760901